- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics
- Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
- Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
- Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, Nuvation Bio Inc (NUVB:NYQ) closed at 2.68, -35.57% below its 52-week high of 4.16, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.63 |
---|---|
High | 2.76 |
Low | 2.61 |
Bid | 2.63 |
Offer | 2.79 |
Previous close | 2.62 |
Average volume | 1.04m |
---|---|
Shares outstanding | 246.69m |
Free float | 185.43m |
P/E (TTM) | -- |
Market cap | 661.14m USD |
EPS (TTM) | -0.3463 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:10 BST.
More ▼